Coxibs - Beyond the GI tract: Renal and cardiovascular issues

Journal of Pain and Symptom Management

Volumn 25, Issue 2 SUPPL., 2003, Pages 41-49

  DeMaria, Anthony N ^a   Weir, Matthew R ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Cardiovascular; COX 1; COX 2; Cyclooxygenase; Hypertension; Myocardial infarction; Prostacyclin; Renal; Safety; Sodium excretion

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; CAPTOPRIL; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ENALAPRIL; INDOMETACIN; LOSARTAN; NAPROXEN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG USE; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL TRACT; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; LOW DRUG DOSE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTOXICITY; PATIENT GUIDANCE; POTASSIUM EXCRETION; PROPHYLAXIS; PROTEIN FUNCTION; PROTEINURIA; REVIEW; SIDE EFFECT; SODIUM EXCRETION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0037321487     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0885-3924(02)00630-9     Document Type: Review

References (50)

1. Bombardier C., Laine L., Reicin A.et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528.
2. Silverstein F.E., Faich G., Goldstein J.L.et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study. a randomized, controlled trial JAMA. 284:2000;1247-1255.
3. Laine L., Harper S., Simon T.et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology. 117:1999;776-783.
4. Langman M.J., Jensen D.M., Watson D.J.et al. Adverse upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. JAMA. 282:1999;1929-1933.
5. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959.
6. Carmichael J., Shankel S.W. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med. 78:1985;992-1000.
7. Toto R.D. The role of prostaglandins in NSAID-induced renal dysfunction. J Rheumatol. 28:1991;22-25.
8. Belton O., Byrne D., Kearney D., Leahy A., Fitzgerald D.J. Cyclooxygenase-1 and -2 -dependent prostacyclin formation in patients with atherosclerosis. Circulation. 102:2000;840-845.
9. Nantel F., Meadows E., Denis D.et al. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett. 457:1999;475-477.
10. Schnermann J., Briggs J.P. The macula densa is worth its salt. J Clin Invest. 104:1999;1007-1009.
11. Weir M.R., Froch L. Weighing the renal effects of NSAIDs and COX-2 inhibitors. Clinical Dilemmas. 1:2000;3-12.
12. Brater D.C. Effects of nonsteroidal anti-inflammatory drugs on renal function. focus on cyclooxygenase-2-selective inhibition Am J Med. 107(Suppl. 6A):1999;65S-71S.
13. Whelton A., Hamilton C.W. Nonsteroidal anti-inflammatory drugs. effects on kidney function J Clin Pharmacol. 31:1991;588-598.
14. Rossat J., Maillard M., Nussberger J., Brunner H.R., Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 66:1999;76-84.
15. Whelton A., Schulman G., Wallemark C.et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 160:2000;1465-1470.
16. Catella-Lawson F., McAdam B., Morrison B.W.et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 289:1999;735-741.
17. Swan S.K., Rudy D.W., Lasseter K.C.et al. Effects of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 133:2000;1-9.
18. Pope J.E., Anderson J.J., Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 153:1993;477-484.
19. Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 121:1994;289-300.
20. Gurwitz J.H., Avorn J., Bohn R.L.et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 272:1994;781-786.
21. Chrischilles E.A., Wallace R.B. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol. 48:1993;91-96.
22. Beckmann M.L., Gerber J.G., Byyny R.L., Lo-Verde M., Nies A.S. Propranolol increases prostacyclin synthesis in patients with essential hypertension. Hypertension. 12:1988;582-588.
23. Polónia J. Interaction of antihypertensive drugs with anti-inflammatory drugs. Cardiology. 88(Suppl. 3):1997;47-51.
24. Houston M.C., Weir M., Gray J.et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med. 155:1995;1049-1054.
25. Polónia J., Bonaventura I., Gama G.et al. Influence of nonsteroidal anti-inflammatory drugs on renal function and 24-hour ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 13:1995;925-931.
26. Morgan T.O., Anderson A., Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 13:2000;1161-1167.
27. Conlin P.R., Moore T.J., Swartz S.L.et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension. 36:2000;461-465.
28. Whelton A., Singh G., White W.et al. Celecoxib does not increease the risk of cardiac failure, edema, or hypertension compared to NSAIDs. Results from SUCCESS-1, a double blind, randomized trial in 13,274 OA patients Ann Rheumat Dis. 60(Suppl. 1):2001;237. (abstract).
29. Cannon G.W., Caldwell J.R., Holt P.et al. Rofecoxib, a specific inhibitor of cyclooxygenase-2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum. 43:2000;978-987.
30. Geba G.P., Polis A.B., Dixon M.E.et al. Comparative blood pressure effects of rofecoxib, celecoxib and placebo in patients with osteoarthritis (OA). a randomized controlled trial Ann Rheum Dis. 60(Suppl. 1):2001;238.
31. Whelton A., Fort J.G., Puma J.A.et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function. a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients Am J Ther. 8:2001;85-95.
32. Wallberg-Jonsson S., Johansson H., Ohman M.L., Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. a retrospective cohort study from disease onset J Rheumatol. 26:1999;2562-2571.
33. Wolfe F., Mitchell D.M., Sibley J.T.et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 37(4):1994;481-494.
34. Rosalki S.B. C-reactive protein. Int J Clin Pract. 55(4):2001;269-270.
35. Koenig W. Inflammation and coronary heart disease. an overview Cardiol Rev. 9:2001;31-35.
36. Libby P., Simon D.I. Inflammation and thrombosis. the clot thickens Circulation. 103:2001;1718-1720.
37. Van Hecken A., Schwartz J.I., Depré M.et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 40:2000;1109-1120.
38. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162:1099-1105.
39. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162:1105-1110.
40. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162:1111-1116.
41. Dalen JE. Selective COX-2 inhibitors, NSAIDs, aspirin and myocardial infarction. Arch Intern Med 162:1091-1092.
42. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;8607:349-360.
43. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ. 308:1994;81-106.
44. Konstam M.A., Weir M.R., Reicin A.et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 104:2001;15-23.
45. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 96:272-277.
46. Murata T., Ushikubi F., Matsuoka T.et al. Altered pain perception and inflammatory responses in mice lacking prostacyclin receptor. Nature. 388(6643):1997;678-682.
47. Reilly I.A., FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo. implications for therapy with platelet inhibitory drugs Blood. 69:1987;180-186.
48. Singh G., Triadafilopoulos G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol. 26(Suppl 56):1999;18-24.
49. Derry S., Loke Y.K. Risk of gastrointestinal hemorrhage with long-term use of aspirin. meta-analysis BMJ. 321:2000;1183-1187.
50. Singh G., Goldstein J., Agrawal N.et al. COX-2 specific inhibitors - is there any benefit of using these agents in patients on low dose aspirin (ASA)? Ann Rheum Dis. 60(Suppl. 1):2001;239.